Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.09 AUD
Change Today +0.003 / 3.66%
Volume 2.0M
ACL On Other Exchanges
As of 12:42 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - A$0.68
52 Week Low
06/30/15 - A$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, engages in developing human therapeutic products based on its proprietary drug discovery and synthesis technologies in Australia and the United States. The company operates through Fondaparinux and HyACT segments. It provides generic Fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. The company also offers HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics. In addition, it is developing HA-Irinotecan that is in the Phase II clinical trials for the treatment of small cell lung cancer. The company has collaboration agreement with Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer. Alchemia Limited was founded in 1995 and is headquartered in Brisbane, Australia.

Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$239.8K
Chief Scientific Officer, Vice President of O...
Total Annual Compensation: A$225.4K
Compensation as of Fiscal Year 2015.

alchemia ltd (ACL) Key Developments

Dr. Reddy's to Buy IP Rights of Alchemia's fondaparinux Drug for INR 1.16 Billion

Dr. Reddy's Laboratories Ltd. announced that it had entered into a binding agreement with Alchemia Ltd. to acquire exclusive global intellectual property rights for its generic anti-coagulant drug fondaparinux sodium for the equivalent of $17,574 million. Under the terms of the sale, Alchemia will receive $17.5 million in cash from Dr. Reddy's at the close of the transaction. In addition, the company received a payment of $1.15 million for its share of net profit from US-only sales of fondaparinux for the quarter ended June 30, 2015 agreement is conditional on shareholder approval, which will be sought at the company's annual general meeting to be held in November. Alchemia was entitled to receive 50% of the net profit generated from sales of fondaparinux in North America. Alchemia has been granted patents over novel synthetic pathways that prevent others from using Alchemia's proprietary process to manufacture fondaparinux until at least 2022.

Alchemia Limited Announces Earnings Results for the Fourth Quarter and Year Ended June 30, 2015

Alchemia Limited announced earnings results for the fourth quarter and year ended June 30, 2015. The company reported a net operating cash outflow of $5.6 million for the quarter ended 30 June 2015. This quarter's net cash burn includes close out of many contracts for the Phase III trial for HA-Irinotecan. For the year, net cash outflows from operating activities totalled $6.2 million, an increase of $4.6 million from the previous year (2014: $1.6 million). The increase in net operating cash outflows was mainly due to decreases in receipts from fondaparinux profit share of $4.1 million, grants and research and development incentives of $2.6 million, and bank interest received of $0.2 million. The group reported a net loss of $15.8 million compared to $6.9 million for the previous year. The current year loss includes an impairment charge (non-cash) of $12.7 million as a result of the intangible assets relating to the HyACT technology being fully impaired in the year as a result of the Phase III trial for HA-Irinotecan failing to meet its primary end point. Total revenue was $11.9 million, a decrease of $2.8 million from the previous period (2014: $14.7 million). This decrease was primarily due to a decrease of fondaparinux profit share income of $2.6 million compared to the previous corresponding period.

Alchemia Limited to Report Fiscal Year 2015 Results on Aug 28, 2015

Alchemia Limited announced that they will report fiscal year 2015 results at 11:08 PM, GMT Standard Time on Aug 28, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.09 AUD +0.003

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at